View on GitHub

Added entries:

  • (FDA) BCR-ABL1 and sensitivity to asciminib in chronic phase chronic myeloid leukemia.
  • (Clinical evidence) SPOP missense somatic variants and favorable prognosis in de-novo metastatic castration-sensitive prostate cancer.
  • (Clinical evidence) SPOP missense somatic variants and sensitivity to abiraterone in metastatic castration-resistant prostate cancer
  • (Clinical evidence) SPOP missense somatic variants and sensitivity to anti-androgen therapy.
  • (Inferential) CD274 amplification and sensitivity to atezolizumab in non-small cell lung cancer.

Revised entries:

  • (FDA) FGFR2 fusions and sensitivity to erdafitnib’s description was revised to match the standard’s described in our S.O.P..